UBS Group
EVMN icon

UBS Group’s Evommune Inc EVMN Stock Holding History

UBS Group’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$173K Sell
20,970
-392,583
-95% -$4.71M ﹤0.01% 6847
2026
Q2 		$5.5M Buy
413,553
+115,178
+39% +$2.68M ﹤0.01% 4074
2026
Q1 		$6.86M Buy
298,375
+294,961
+8,640% +$6.67M ﹤0.01% 3742
2025
Q4 		$58.4K Buy
+3,414
New +$64.1K ﹤0.01% 7146

Other funds holding EVMN

EQT Fund Management
EQT Fund Management Luxembourg $947M AUM 19.95% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return
Nan Fung Group Holdings
Nan Fung Group Holdings Kai Tak, Hong Kong $150M AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group's EVMN Position: Q3 2026 in Review

UBS Group reduced its Evommune Inc (EVMN) stake by 95% in Q3 2026, selling an estimated $4.71M and leaving 20,970 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #6847.

UBS Group first reported a position in EVMN in Q4 2025 and has held it in 4 quarters since. The position peaked at $6.86M in Q1 2026. 63 funds tracked by Wall St. Rank hold EVMN as of Q3 2026.

  • UBS Group held 20,970 shares of Evommune Inc worth $173K as of Q3 2026.
  • UBS Group sold 392,583 Evommune Inc shares in Q3 2026, an estimated $4.71M.
  • Evommune Inc made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6847 holding.
  • UBS Group first reported a position in Evommune Inc in Q4 2025 and has held it in 4 quarters since.
  • UBS Group's Evommune Inc position peaked at $6.86M in Q1 2026.
  • 63 funds tracked by Wall St. Rank held Evommune Inc as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.